Clinical Trials Directory

Trials / Completed

CompletedNCT00833703

Long Term Safety of Clopidogrel in Neonates/Infants With Systemic to Pulmonary Artery Shunt Palliation

Long Term Safety Study in Patients Included in the CLARINET Study With Cyanotic Congenital Heart Disease Palliated With a Systemic-to-pulmonary Artery Shunt and for Whom the Shunt is Still in Place at One Year of Age

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
49 (actual)
Sponsor
Sanofi · Industry
Sex
All
Age
12 Months
Healthy volunteers
Not accepted

Summary

This study is the extension of the CLARINET study \[NCT00396877 -EFC5314\] in neonates or infants with cyanotic congenital heart disease palliated with a systemic-to-pulmonary artery shunt. The primary objective was to assess the safety up to 18 months of age of the extended use of Clopidogrel 0.2 mg/kg/day in patients for whom the shunt was still in place at one year of age. The secondary objective was to assess the efficacy on the occurrence of shunt thrombosis requiring intervention or any death.

Detailed description

Patients remained in the treatment group to which they were originally allocated for the CLARINET study and continued blindly their treatment (0.2 mg/kg/day of clopidogrel or placebo) up to the occurrence of shunt thrombosis, next surgical procedure for correction of the congenital heart disease, death, or 18 months of age, whichever came first. The maximum treatment duration were 6 months.

Conditions

Interventions

TypeNameDescription
DRUGClopidogrelForm: reconstituted solution using Clopidogrel powder Route: oral or enteric Frequency: once daily Dose: daily dose adjusted for weight
DRUGplaceboForm: reconstituted solution using matching placebo powder Route: oral or enteric Frequency: once daily Dose: daily dose adjusted for weight

Timeline

Start date
2009-01-01
Primary completion
2010-07-01
Completion
2010-07-01
First posted
2009-02-02
Last updated
2011-08-22
Results posted
2011-08-16

Locations

15 sites across 15 countries: United States, Brazil, France, Germany, Hungary, India, Italy, Malaysia, Mexico, Poland, Portugal, Russia, Spain, Taiwan, United Kingdom

Source: ClinicalTrials.gov record NCT00833703. Inclusion in this directory is not an endorsement.